

**Clinical Trials Summary for out of hours  
Important Reference**

<b>Acronym study title</b>	IMMU-132-13/TROPiCS-04  IRAS Ref: 1003505
<b>Study Details</b>	A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
<b>Principal Investigator / Sub-Is</b>	Professor Alison Birtle <a href="mailto:Alison.birtle@lthtr.nhs.uk">Alison.birtle@lthtr.nhs.uk</a>  01772 52 4762  <u>Sub-Is:</u> Dr Natalie Charnley <a href="mailto:Natalie.charnley@lthtr.nhs.uk">Natalie.charnley@lthtr.nhs.uk</a>  Dr Omi Parikh <a href="mailto:Omi.parikh@lthtr.nhs.uk">Omi.parikh@lthtr.nhs.uk</a>
<b>Research Nurse Team</b>	Amanda Cook 01772 52 4656  Sheila Calvert 01772 52 3921
<b>Drug therapy</b>	Randomised to either: <a href="#">Sacituzumab Govitecan Versus Treatment of Physician's Choice</a> (Our standard of care would probably be weekly paclitaxel)  <a href="#">Sacituzumab govitecan is not currently in use but Dave Barber has just written the D&amp;T application form for it so the Trust maybe using it soon (for breast cancer). Protocol is on the network website under breast cancer</a>
<b>In the event that a patient calls this hotline for advice</b>	Please treat as per clinical protocols and inform the clinical and research teams.  The medical monitor name and contact information:  24-Hour Emergency Contact: PRA Medical Monitor Email: <a href="mailto:IMD13213@prahs.com">IMD13213@prahs.com</a>  +49 621 878 2850 (Direct)